Opinion | Published:

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Nature Reviews Cancer volume 15, pages 668679 (2015) | Download Citation

Abstract

High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719–725 (2011).

  2. 2.

    The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).

  3. 3.

    et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front. Biosci. (Elite Ed) 3, 625–634 (2011).

  4. 4.

    et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26–35 (2007).

  5. 5.

    et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195, 451–456 (2001).

  6. 6.

    , , & Ovarian cancer risk after salpingectomy: a nationwide population-based study. J. Natl. Cancer Inst. 107 (2015).

  7. 7.

    et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesions. J. Pathol. 226, 421–426 (2012).

  8. 8.

    et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161–169 (2007).

  9. 9.

    et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751–765 (2013).

  10. 10.

    , , & The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology 156, 1975–1981 (2015).

  11. 11.

    et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am. J. Surg. Pathol. 39, 287–293 (2015).

  12. 12.

    et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 24, 1248–1253 (2011).

  13. 13.

    et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56 (2010).

  14. 14.

    The Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian cancer. Nature 474, 609–615 (2011).

  15. 15.

    et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).

  16. 16.

    et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 15, 526 (2014).

  17. 17.

    et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).

  18. 18.

    et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344–2351 (2010).

  19. 19.

    et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 72, 5675–5682 (2012).

  20. 20.

    et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654–2663 (2012).

  21. 21.

    et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl Acad. Sci. USA 107, 12629–12633 (2010).

  22. 22.

    et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).

  23. 23.

    et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).

  24. 24.

    , & Poly (adp-ribose) polymerase inhibitors: recent advances and future development. J. Clin. Oncol. 33, 1397–1406 (2015).

  25. 25.

    et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141–1152 (2014).

  26. 26.

    et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 5, e15498 (2010).

  27. 27.

    et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).

  28. 28.

    et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst. 106, dju249 (2014).

  29. 29.

    et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).

  30. 30.

    et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26, 77–91 (2014).

  31. 31.

    et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23, 186–199 (2013).

  32. 32.

    et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl Acad. Sci. USA 110, 9845–9850 (2013).

  33. 33.

    et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Commun. 5, 2977 (2014).

  34. 34.

    et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

  35. 35.

    et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 8, e72162 (2013).

  36. 36.

    , , , & Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).

  37. 37.

    et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS ONE 9, e103988 (2014).

  38. 38.

    et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE 9, e90604 (2014).

  39. 39.

    et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun. 6, 7419 (2015).

  40. 40.

    et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat. Commun. 6, 6220 (2015).

  41. 41.

    et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124, 4614–4628 (2014).

  42. 42.

    & Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 7, 1755–1764 (2012).

  43. 43.

    , & Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl Acad. Sci. USA 108, 7547–7552 (2011).

  44. 44.

    et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 13, 899–911 (2011).

  45. 45.

    et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J. Pathol. 233, 228–237 (2014).

  46. 46.

    et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).

  47. 47.

    et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol. Oncol. 8, 656–668 (2014).

  48. 48.

    et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 20, 1288–1297 (2014).

  49. 49.

    et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 5, 8750–8764 (2014).

  50. 50.

    et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 74, 6980–6990 (2014).

  51. 51.

    , & One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 344, 1–12 (2014).

  52. 52.

    et al. Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin. Cancer Res. 17, 2195–2206 (2011).

  53. 53.

    et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231, 21–34 (2013).

  54. 54.

    et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 72, 4060–4073 (2012).

  55. 55.

    et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29, 4905–4913 (2010).

  56. 56.

    et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 12, e1001789 (2015).

  57. 57.

    et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).

  58. 58.

    et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13, 1069–1080 (2011).

  59. 59.

    et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008–3015 (2011).

  60. 60.

    et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 (2008).

  61. 61.

    et al. Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. Eur. J. Cancer 50, 7 (2014).

  62. 62.

    et al. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10, 1071–1092 (2014).

  63. 63.

    et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).

  64. 64.

    Cancer: A most exceptional response. Nature 520, 389–393 (2015).

  65. 65.

    et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014).

  66. 66.

    , , & Immunotherapy for ovarian cancer: what's next? J. Clin. Oncol. 29, 925–933 (2011).

  67. 67.

    et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 20, 1125–1134 (2014).

  68. 68.

    , & The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225–232 (2012).

  69. 69.

    et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 115, 185–192 (2009).

  70. 70.

    , & Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900–6912 (2013).

  71. 71.

    & Deciphering and reversing tumor immune suppression. Immunity 39, 61–73 (2013).

  72. 72.

    et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67, 8900–8905 (2007).

  73. 73.

    & Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

  74. 74.

    et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).

  75. 75.

    et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

  76. 76.

    , , , & Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).

  77. 77.

    et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin. Cancer Res. 19, 3474–3484 (2013).

  78. 78.

    et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod. Pathol. 25, 625–636 (2012).

  79. 79.

    et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am. J. Surg. Pathol. 36, 1170–1177 (2012).

  80. 80.

    et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22, 393–402 (2009).

  81. 81.

    et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306, 1557–1565 (2011).

  82. 82.

    et al. Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells. Proc. Natl Acad. Sci. USA 112, 2157–2162 (2015).

  83. 83.

    et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 232, 199–209 (2014).

  84. 84.

    , , & The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26 (2013).

  85. 85.

    et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4, 2067–2079 (2013).

  86. 86.

    et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5, 587–598 (2014).

  87. 87.

    et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin. Cancer Res. 20, 6504–6516 (2014).

  88. 88.

    et al. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 5, 3579–3589 (2014).

  89. 89.

    et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72, 2197–2205 (2012).

  90. 90.

    et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281–3292 (2012).

  91. 91.

    et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083–6096 (2011).

  92. 92.

    et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).

  93. 93.

    et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).

  94. 94.

    et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J. Clin. Invest. 124, 2611–2625 (2014).

  95. 95.

    et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 1, 144–157 (2011).

  96. 96.

    et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 73, 5016–5028 (2013).

  97. 97.

    et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin. Cancer Res. 20, 711–723 (2014).

  98. 98.

    et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).

  99. 99.

    et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12, 514–527 (2007).

  100. 100.

    et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).

  101. 101.

    et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).

  102. 102.

    et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

  103. 103.

    et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).

  104. 104.

    et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776–1782 (2012).

  105. 105.

    et al. Results of ARIEL2: A phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J. Clin. Oncol. 33, 5508 (2015).

  106. 106.

    et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).

  107. 107.

    et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).

  108. 108.

    et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).

  109. 109.

    et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014).

  110. 110.

    & Ovarian cancer and antiangiogenic therapy: caveat emptor. J. Clin. Oncol. 32, 3353–3356 (2014).

  111. 111.

    et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br. J. Cancer 108, 250–258 (2013).

  112. 112.

    et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J. Clin. Oncol. 32, 5502 (2014).

  113. 113.

    et al. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 34, 19–40 (2015).

  114. 114.

    et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin. Cancer Res. 19, 809–820 (2013).

  115. 115.

    et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 15, 1207–1214 (2014).

  116. 116.

    , & The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. Cancer Discov. 1, 17–20 (2011).

  117. 117.

    et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. USA 108, 12372–12377 (2011).

  118. 118.

    et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl Acad. Sci. USA 112, 232–237 (2015).

  119. 119.

    et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

  120. 120.

    et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436–442 (2014).

  121. 121.

    , , , & Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283–290 (2003).

  122. 122.

    et al. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov. 2, 156–171 (2012).

  123. 123.

    et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).

  124. 124.

    et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

  125. 125.

    et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat. Genet. 46, 427–429 (2014).

  126. 126.

    et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71, 3991–4001 (2011).

  127. 127.

    et al. β-catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene 34, 2297–2308 (2015).

  128. 128.

    et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 74, 4922–4936 (2014).

  129. 129.

    et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl Acad. Sci. USA 111, 17266–17271 (2014).

  130. 130.

    & Cracking open window of opportunity trials. J. Clin. Oncol. 30, 2573–2575 (2012).

  131. 131.

    , , , & Early versus delayed treatment of relapsed ovarian cancer. Lancet 377, 380–381 (2011).

  132. 132.

    et al. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 137, 1136–1146 (2014).

  133. 133.

    et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J. Natl. Cancer Inst. 106, djt431 (2014).

  134. 134.

    , , , & Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann. Oncol. 4, 787–792 (2014).

  135. 135.

    et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119, 555–562 (2013).

  136. 136.

    et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am. J. Obstet. Gynecol. 212, e1–479.e10 (2014).

  137. 137.

    Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385, 1835–1842 (2015).

  138. 138.

    Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 9, e1001200 (2012).

  139. 139.

    et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J. Natl Cancer Inst. 105, 823–832 (2013).

  140. 140.

    et al. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol. Oncol. 128, 483–487 (2013).

  141. 141.

    et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J. Clin. Oncol. 32, 1249–1255 (2014).

  142. 142.

    et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet. Gynecol. 120, 235–240 (2012).

  143. 143.

    et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum. Mol. Genet. 23, 4703–4709 (2014).

  144. 144.

    et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014).

  145. 145.

    et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J. Natl Cancer Inst. 107, 380 (2015).

  146. 146.

    et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J. Natl Cancer Inst. 107, 379 (2015).

  147. 147.

    et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet. Gynecol. 115, 945–952 (2010).

  148. 148.

    et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat. Genet. 44, 475–476 (2012).

  149. 149.

    et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat. Genet. 43, 879–882 (2011).

  150. 150.

    et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42, 410–414 (2010).

  151. 151.

    et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat. Genet. 43, 1104–1107 (2011).

  152. 152.

    et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat. Genet. 47, 164–171 (2015).

  153. 153.

    et al. Biopsychological stress factors in BRCA mutation carriers. Psychosomatics 53, 582–590 (2012).

  154. 154.

    Biomarkers, the molecular gaze and the transformation of cancer survivorship. Biosocieties 8, 124–143 (2013).

  155. 155.

    et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet. Gynecol. 121, 14–24 (2013).

  156. 156.

    et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am. J. Obstet. Gynecol. 210, 471e1-11 (2014).

  157. 157.

    et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol. Biomarkers Prev. 24, 671–676 (2015).

  158. 158.

    et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295–2303 (2011).

  159. 159.

    et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening. J. Clin. Oncol. 33, 2062–2071 (2015).

  160. 160.

    et al. Does aggressive surgery improve outcomes? interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J. Clin. Oncol. 33, 937–943 (2015).

  161. 161.

    , & Ovarian cancer screening—current status, future directions. Gynecol. Oncol. 132, 490–495 (2014).

  162. 162.

    et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J. Clin. Oncol. 31, 387–392 (2013).

  163. 163.

    et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl Med. 4, 136ra68 (2012).

  164. 164.

    et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl Med. 5, 167ra4 (2013).

  165. 165.

    et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol. Oncol. 120, 385–392 (2011).

  166. 166.

    et al. Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin. Cancer Res. 20, 1313–1322 (2014).

  167. 167.

    , , , & Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72, 278–287 (1999).

  168. 168.

    et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115, 1234–1244 (2009).

  169. 169.

    et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943–953 (2010).

  170. 170.

    , , , & A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG 115, 1713–1714 (2008).

  171. 171.

    , & Artificial intelligence systems as prognostic and predictive tools in ovarian cancer. Ann. Surg. Oncol. 22, 3970–3975 (2015).

  172. 172.

    et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur. J. Cancer 49, 3191–3201 (2013).

  173. 173.

    et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl Cancer Inst. 106, dju048 (2014).

  174. 174.

    , , & A framework for a personalized surgical approach to ovarian cancer. Nat. Rev. Clin. Oncol. 12, 239–245 (2015).

  175. 175.

    et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 21, 289–295 (2011).

  176. 176.

    et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13, 1702–1710 (2006).

  177. 177.

    et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann. Surg. Oncol. 20, 1348–1354 (2013).

  178. 178.

    & Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

  179. 179.

    , , & Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 148, 719–725 (2007).

  180. 180.

    , & Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl. Immunohistochem Mol. Morphol. 19, 293–299 (2011).

  181. 181.

    et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am. J. Surg. Pathol. 34, 627–635 (2010).

  182. 182.

    et al. CPTAC Assay Portal: a repository of targeted proteomic assays. Nat. Methods 11, 703–704 (2014).

  183. 183.

    et al. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2, 21 (2014).

  184. 184.

    et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol. Oncol. 123, 5–12 (2011).

Download references

Author information

Affiliations

  1. Cancer Genomics and Genetics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 8006, Australia; and the Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, Sydney, 2010 New South Wales, Australia.

    • David D. Bowtell
  2. Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.

    • Steffen Böhm
    •  & Frances R. Balkwill
  3. Nuffield Department of Obstetrics and Gynaecology and the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK.

    • Ahmed A. Ahmed
  4. Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.

    • Paul-Joseph Aspuria
    •  & Beth Y. Karlan
  5. MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030–4009, USA.

    • Robert C. Bast Jr
    • , Karen H. Lu
    •  & Anil K. Sood
  6. University of Oxford, Headington, Oxford, OX3 7LF, UK.

    • Valerie Beral
  7. Stanford University, Stanford, California 94305, USA.

    • Jonathan S. Berek
  8. Massachusetts General Hospital, Boston, Massachusetts 02114 USA.

    • Michael J. Birrer
  9. Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.

    • Sarah Blagden
    • , Christina Fotopoulou
    • , Hani Gabra
    •  & Euan A. Stronach
  10. Arizona Oncology, Tucson, Arizona 85711, USA.

    • Michael A. Bookman
  11. Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.

    • James D. Brenton
    •  & Filipe Correia Martins
  12. The Sidney Kimmel Cancer Center at John Hopkins University, Baltimore, Maryland 21287, USA.

    • Katherine B. Chiappinelli
  13. University Hospital of Lausanne, Lausanne, Switzerland.

    • George Coukos
  14. University of Pennsylvania, Penn Ovarian Cancer Research Center, Philadelphia, Pennsylvania 19104, USA.

    • Ronny Drapkin
  15. University of Manchester, Manchester M13 9WL, UK.

    • Richard Edmondson
  16. Institut National de la Santé et de la Recherche Médicale, UMRS1138, Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Université Paris Descartes, Sorbonne Paris Cité, Sorbonne Universités, UPMC Univ Paris 06, 75006 Paris, France.

    • Jérôme Galon
  17. Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK.

    • Charlie Gourley
  18. Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.

    • Valerie Heong
    •  & Clare L. Scott
  19. University of British Columbia, Departments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, Faculty of Medicine, Vancouver, British Columbia V6T 2B5, Canada.

    • David G. Huntsman
  20. Harvard Medical School, Boston, Massachusetts 02115, USA.

    • Marcin Iwanicki
  21. Ovarian Cancer Action, London NW1 OJH, UK.

    • Allyson Kaye
  22. University of Chicago, Chicago, Illinois 60637, USA.

    • Ernst Lengyel
    •  & Iris L. Romero
  23. Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

    • Douglas A. Levine
  24. University of Glasgow, Glasgow G61 1QH, UK.

    • Iain A. McNeish
  25. Women's Cancer, Institute for Women's Health, University College London, London WC1E 6BT, UK.

    • Usha Menon
  26. Women's College Research Institute, Toronto, Ontario M5G 1N8, Canada.

    • Steven A. Narod
  27. British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, Canada.

    • Brad H. Nelson
  28. Indiana University School of Medicine & Simon Cancer Center, Bloomington, IN 47405–4401, USA.

    • Kenneth P. Nephew
  29. University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.

    • Paul Pharoah
  30. University of Pennsylvania, Philadelphia, PA 19104–5156, USA.

    • Daniel J. Powell Jr
  31. Translational Genomics Research Institute (Tgen), Phoenix, Arizona 85004, USA.

    • Pilar Ramos

Authors

  1. Search for David D. Bowtell in:

  2. Search for Steffen Böhm in:

  3. Search for Ahmed A. Ahmed in:

  4. Search for Paul-Joseph Aspuria in:

  5. Search for Robert C. Bast in:

  6. Search for Valerie Beral in:

  7. Search for Jonathan S. Berek in:

  8. Search for Michael J. Birrer in:

  9. Search for Sarah Blagden in:

  10. Search for Michael A. Bookman in:

  11. Search for James D. Brenton in:

  12. Search for Katherine B. Chiappinelli in:

  13. Search for Filipe Correia Martins in:

  14. Search for George Coukos in:

  15. Search for Ronny Drapkin in:

  16. Search for Richard Edmondson in:

  17. Search for Christina Fotopoulou in:

  18. Search for Hani Gabra in:

  19. Search for Jérôme Galon in:

  20. Search for Charlie Gourley in:

  21. Search for Valerie Heong in:

  22. Search for David G. Huntsman in:

  23. Search for Marcin Iwanicki in:

  24. Search for Beth Y. Karlan in:

  25. Search for Allyson Kaye in:

  26. Search for Ernst Lengyel in:

  27. Search for Douglas A. Levine in:

  28. Search for Karen H. Lu in:

  29. Search for Iain A. McNeish in:

  30. Search for Usha Menon in:

  31. Search for Steven A. Narod in:

  32. Search for Brad H. Nelson in:

  33. Search for Kenneth P. Nephew in:

  34. Search for Paul Pharoah in:

  35. Search for Daniel J. Powell in:

  36. Search for Pilar Ramos in:

  37. Search for Iris L. Romero in:

  38. Search for Clare L. Scott in:

  39. Search for Anil K. Sood in:

  40. Search for Euan A. Stronach in:

  41. Search for Frances R. Balkwill in:

Competing interests

The following authors declare competing interests: D.D.B. has received research grant funding from Astra Zeneca, Pfizer and Roche. M.A.B. declares participation in ad-hoc advisory boards regarding investigational (non-marketed) agents for development of clinical trials in ovarian cancer, including AbbVie, AstraZeneca, Novartis, Sanofi-Aventis, Clovis, Daiichi-Sankyo, Cerulean, Emdocyte, Immunogen, Oxigene, Genentech-Roche and Boehringer Ingelheim. He declares financial compensation and travel support for these meetings. He has participated in Independent Data Monitoring Committees (IDMC) for Phase III trials in ovarian cancer for Genentech-Roche and Boehringer Ingelheim, with financial compensation for time and travel. J.D.B. is cofounder and own shares in Inivata Ltd. R.C.B. has royalties from Fujirebio Diagnostics. G.C. has undertaken consultancies for Roche, Sanofi and Pierre-Fabre, and has grants or support for research from Boehringer Ingelheim. R.D. is on the scientific advisory board of Siamab Therapeutics. C.G's employer (Edinburgh University) has received payments for his attendance at advisory boards from Roche, AstraZeneca and Nucana, for his lectures from Roche and AstraZeneca, and for clinical research from AstraZeneca, Aprea and GlaxoSmithKline. He is named as an inventor on issued patents and patent applications regarding the Almac AADX assay. J.G. is cofounder and shareholder of HalioDx Biotech company. D.G.H. is founder, shareholder and Chief Medical Officer of Contextual Genomics. B.Y.K. has grants or support for research from AstraZeneca, Tesaro, Dana-Farber Cancer Center/NCI, Amgen and Cancer International Research Group, and is co-inventor of 'Molecular Signatures of Ovarian Cancer', patent pending. D.A.L. declares speaking honoraria from Roche Products, has a patent application on Detection of Ovarian Cancer and stock options in Critical Outcomes Technologies I.A.M. is on advisory boards for Clovis Oncology, Astra Zeneca and Roche. U.M. owns stock in Abcodia that has an interest in early detection of ovarian cancer. D.J.P. has obtained consulting fees from Lion Biotherapeutics, research funding through an alliance between The University of Pennsylvania and Novartis, and patents on the application of chimeric antigen receptors in oncology. C.L.S. has had honoraria, travel and accommodation expenses from Roche, Astra Zeneca, Clovis Oncology and given expert testimony for Astra Zeneca and Speakers' Bureau Prime Oncology. All other authors declare no competing interests.

Corresponding authors

Correspondence to David D. Bowtell or Frances R. Balkwill.

Supplementary information

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrc4019

Further reading